Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women

NCT02400567 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02400567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02400567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
September 30, 2020
Enrollment
125 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant operable breast cancer